Paul M. Schneider

Klinik Hirslanden

Papers

2

Total Citations

155

H-Index

2

About

Paul M. Schneider is a leading figure in esophageal surgical oncology, whose work has fundamentally advanced the treatment of esophageal adenocarcinoma. His primary research focuses on refining and comparing surgical techniques to improve patient outcomes, with a particular emphasis on minimally invasive and robotic-assisted approaches. Dr. Schneider is best known for his leadership in the landmark ROBOT-2 trial, a randomized controlled trial that directly compared robot-assisted minimally invasive thoraco-laparoscopic esophagectomy (RAMIE) to conventional minimally invasive esophagectomy (MIE). This pivotal study, cited over 100 times, provides crucial evidence on the efficacy and safety of robotic surgery for resectable esophageal cancer. Beyond this trial, his 2018 review on the evolution of surgical approaches for esophageal cancer, with 54 citations, serves as a definitive guide for surgeons navigating the technical challenges and steep learning curve of MIE. Through his rigorous clinical research, Dr. Schneider has not only shaped modern surgical protocols but also provided the data necessary for surgeons to adopt and master these complex, life-saving procedures.

Research Focus

Key Achievements

2
H-Index
2
Papers
155
Total Citations
78
Avg Citations/Paper
🏆 Most Cited Paper
Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy versus minimally invasive esophagectomy for resectable esophageal adenocarcinoma, a randomized controlled trial (ROBOT-2 trial)
101 citations · 2021
📈 Most Prolific Year: 2021 (1 Papers)
🤝 Key Collaborators: 17
🏛 Institutions: Klinik Hirslanden

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 14 days ago